AstraZeneca is trading 6.1% down at £11864 following reports of preliminary merger talks with Bristol Myers Squibb to create a $400 billion pharmaceutical giant.
- Investors are reacting to concerns regarding deal complexity, valuation, and significant execution risks.
- The stock is notably underperforming the broader market, where major U.S. equity futures are currently trading modestly higher.